However, clinical studies indicate that AD patients with poorer cognitive function exhibit elevated OCN levels, and both plasma and cerebrospinal fluid OCN levels are significantly correlated with cerebral Aβ deposition, tau hyperphosphorylation (pTau), neurodegeneration, and cognitive decline [97]. The gene discussed is MAPT; the disease is Alzheimer disease.